BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
March 06 2024 - 5:45AM
UK Regulatory
BioNTech to Report Fourth Quarter and Full Year 2023 Financial
Results and Provide Corporate Update on March 20, 2024
MAINZ, Germany, March 6, 2024 (GLOBE
NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the
Company”) will announce its financial results for the full year and
fourth quarter 2023 on Wednesday, March 20, 2024. Additionally, the
Company will host a conference call and webcast that day at 8:00
a.m. ET (2:00 p.m. CET) for investors, financial analysts and the
general public to discuss its financial results and provide a
corporate update.
To access the live conference call via
telephone, please register via this link. Once registered, dial-in
numbers and a PIN will be provided. It is recommended to register
at least one day in advance. The slide presentation and audio of
the webcast will be available via this link.
Participants may also access the slides and the
webcast of the conference call via the “Events & Presentations”
page in the Investor Relations section of the Company’s website
at https://biontech.com/. A replay of the webcast will be made
available shortly after the call and archived on the Company’s
website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is
a next generation immunotherapy company pioneering novel therapies
for cancer and other serious diseases. The Company exploits a wide
array of computational discovery and therapeutic drug platforms for
the rapid development of novel biopharmaceuticals. Its broad
portfolio of oncology product candidates includes individualized
and off-the-shelf mRNA-based therapies, innovative chimeric antigen
receptor T cells, bispecific immune checkpoint modulators, targeted
cancer antibodies and small molecules. Based on its deep expertise
in mRNA vaccine development and in-house manufacturing
capabilities, BioNTech is developing multiple mRNA vaccine
candidates for evaluation for a range of infectious diseases
alongside its diverse oncology pipeline, either on its own or
together with collaborators. BioNTech has established a broad set
of relationships with multiple global pharmaceutical collaborators,
including DualityBio, Fosun Pharma, Genentech, a member of the
Roche Group, Genevant, Genmab, OncoC4, Regeneron and Pfizer.
For more information, please visit
www.BioNTech.com.
CONTACTS
Investor Relations
Victoria Meissner, M.D.
+1 617 528 8293
Investors@biontech.de
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
Biontech (LSE:0A3M)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biontech (LSE:0A3M)
Historical Stock Chart
From Apr 2023 to Apr 2024
